Issued on behalf of Premaitha Health plc
Manchester, UK: Monday, 16 March 2015
Notice of Patent Infringement Proceedings
Manchester, UK – 16 March 2015 – Premaitha Health plc (“Premaitha” AIM: NIPT) an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal testing (NIPT) has been informed that Illumina, Inc. and its wholly-owned subsidiary Verinata Health Inc., have filed a patent infringement suit against Premaitha in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. The patents asserted are European Patent (UK) 0 994 963 B2 and European Patent (UK) 1 981 995 B1.
The Directors believe that the IONA® test does not infringe the patents as claimed by Illumina.
The Company will update the market in respect of further developments, as appropriate.
– Ends –
About Premaitha Health plc
Premaitha Health (AIM: NIPT) is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications. Premaitha’s flagship product, the IONA® test is the first non-invasive in vitro diagnostic CE marked product for prenatal screening enabling clinical laboratories to offer a regulated NIPT in-house.
The IONA® test estimates the risk of a fetus having Down’s syndrome or other serious genetic diseases. The IONA® test has a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and their doctors greater confidence in the result and reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress.
The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their own facilities. This supports Premaitha’s strategy of accelerating the broad dissemination of NIPT tests to ensure that their benefits are available to pregnant women everywhere.
Premaitha is listed on the AIM market of the London Stock Exchange. Premaitha is ISO 13485 certified and its R&D, manufacturing and commercial operation is located at Manchester Science Park, UK.
For further information please visit www.premaitha.com or email firstname.lastname@example.org.
For more information, please contact:
Premaitha Health plc
Dr Stephen Little, Chief Executive Officer
Joanne Cross, Marketing Communications
Tel: +44 (0) 161 667 6865
+44 (0) 7736 843052
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Avi Robinson
Tel: +44 (0) 20 7148 7900
Panmure Gordon (UK) Limited (Broker)
Robert Naylor / Freddy Crossley / Maisie Rose Atkinson
Tel: +44 (0) 20 7886 2500
Instinctif Partners (Media)
Melanie Toyne Sewell / Jen Lewis / Emma Barlow
Tel: +44 (0) 207 457 2020